Manufacturing

Articles

Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.

WuXi AppTec Acquires OXGENE to Increase Cell and Gene Therapy Offerings

The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.

Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

VIVEbiotech to Expand Facilities for Lentiviral-Vector Manufacturing

The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.

Bristol Myers Squibb to Open New Cell Therapy Facility in Massachusetts

The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.

Charles River to Acquire Cognate BioServices for $875 Million

Integration of Brooks Life Sciences BioStore III automated storage and inventory monitoring solution with Cytiva’s Chronicle software will improve traceability, process control, and monitoring capabilities.

Cytiva Integrates Brooks Life Sciences Automated Cold Chain Storage Platform

The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers. 

FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment

Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.

AbbVie to Collaborate with Caribou Biosciences on CAR-T Cell Therapeutics

Through the agreement, Catalent will manufacture Trizell’s Phase I cell therapy for the treatment of micro- and macroangiopathies at its Belgium facility. 


Catalent to Partner with Trizell for Cell Therapy Manufacturing 

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

Manufacturing, Cell Therapies